Patients on multiple daily injections (MDI) insulin therapy and Dexcom CGM saw greater A1C reduction than those on pump therapy and self-monitoring of blood glucose (SMBG).1
See why a continuous glucose monitoring (CGM) system is the right choice for optimizing your patient's diabetes treatment plan.
Medicare now provides coverage for therapeutic CGM systems (those approved for use in making diabetes treatment decisions). The Dexcom G5® CGM System is the first therapeutic CGM system covered as a Medicare benefit.
SAN DIEGO – June 11, 2018 – Dexcom, Inc. (NASDAQ:DXCM), the leader in continuous glucose monitoring for people with diabetes, announced today the U.S. Centers for Medicare & Medicaid Services (CMS) is updating its policy on mobile device...
CogniMed Inc. and Evolve Medical Education jointly provide this education program in conjunction with the...
Soupal J, Petruzelkova L, Flekac M, et al. Comparison of Different Treatment Modalities for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of Follow-Up: A COMISAIR Study. Diabetes Technol Ther. 2016;18(9):532-538.
Beck RW, Riddlesworth T, Ruedy K, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial. JAMA. 2017;317(4):371-378.